

BioTime to Present at the 8th Annual LD Micro Invitational

May 30, 2018

ALAMEDA, Calif.--(BUSINESS WIRE)--May 30, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Russell Skibsted, Chief Financial Officer of BioTime, will be presenting at the 8th Annual LD Micro Invitational Conference on Monday, June 4, 2018 at 1:30pm PT, at the Luxe Sunset Bel Air Hotel in Los Angeles, California.

Mr. Skibsted will also be meeting with investors throughout the conference. One-on-one meetings with Mr. Skibsted may be scheduled through the LD Micro 1x1 desk or by contacting David Nakasone, Director of Investor Relations at BioTime, at 510-871-4188 or dnakasone@biotime.com.

A webcast of Mr. Skibsted's presentation at this conference will be available at the [Events and Presentations](#) section of the BioTime website.

The LD Micro conference will be held at the Luxe Sunset Bel Air Hotel, will feature 230 companies in the small-cap / micro-cap space, and will be attended by over 1,000 individuals.

About BioTime, Inc.

BioTime is a clinical-stage biotechnology company focused on degenerative diseases. Its clinical programs are based on two platform technologies: cell replacement and cell/drug delivery. With its cell replacement platform, BioTime is producing new cells and tissues with its proprietary pluripotent cell technologies. These cells and tissues are developed to replace those that are either rendered dysfunctional or lost due to degenerative diseases or injuries. BioTime's cell/drug delivery programs are based upon its proprietary HyStem[®] cell and drug delivery matrix technology. HyStem[®] was designed, in part, to provide for the transfer, retention and/or engraftment of cellular replacement therapies. BioTime's lead cell delivery clinical program is Renevia[®], which consists of HyStem[®] combined with the patient's own adipose (fat) progenitor cells. Renevia[®] met its primary endpoint in an EU pivotal clinical trial for the treatment of facial lipoatrophy in HIV patients in 2017. BioTime has submitted Renevia[®] for CE Mark approval in the EU. There were no device related serious adverse events reported to date. BioTime's lead cell replacement product candidate is OpRegen[®], a retinal pigment epithelium transplant therapy, which is in a Phase I/IIa multicenter clinical trial for the treatment of dry age-related macular degeneration, the leading cause of blindness in developing countries. There were no unexpected serious adverse events reported to date. BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. (NYSE American: AST) and OncoCyte Corporation (NYSE American: OCX), and a private company, AgeX Therapeutics, Inc.

BioTime common stock is traded on the NYSE American and TASE under the symbol BTX. For more information, please visit www.biotime.com or connect with the company on [Twitter](#), [LinkedIn](#), [Facebook](#), [YouTube](#), and [Google+](#).

To receive ongoing BioTime corporate communications, please click on the following link to join the Company's email alert list: <http://news.biotime.com>.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180530005338/en/>

Source: BioTime, Inc.

BioTime
David Nakasone, 510-871-4188
[Dnakasone@biotime.com](mailto:dnakasone@biotime.com)